Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12856618 | 1.00 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL12856607 | 1.00 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL19785072 | 0.81 | — | — | |
| SCHEMBL22013335 | 0.71 | — | — | |
| SCHEMBL19046909 | 0.69 | — | — | |
| SCHEMBL25811023 | 0.69 | — | — | |
| SCHEMBL25811024 | 0.67 | CHRNB2 (0.30) | — | |
| SCHEMBL19784988 | 0.65 | — | — | |
| SCHEMBL25811022 | 0.63 | — | — | |
| SCHEMBL19046910 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293256-B2 | Sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2012-10-23 | — | — | US | disclosed |
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2011-02-24 | — | — | US | disclosed |
| US-7887824-B2 | such as N,N'-bis(2-hydroxyethyl)sulfamide; improved elasticity on stratum corneum | L'OREAL (FR) | 2011-02-15 | — | — | US | disclosed |
| EP-1669060-B9 | New sulfamide derivatives and their cosmetic use | OREAL (FR) | 2008-12-03 | — | — | EP | disclosed |
| EP-1669060-B1 | New sulfamide derivatives and their cosmetic use | OREAL (FR) | 2008-05-07 | — | — | EP | disclosed |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | L'OREAL (FR) | 2006-06-22 | — | — | US | disclosed |
| EP-1669060-A1 | New sulfamide derivatives and their cosmetic use | L'OREAL (FR) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044918-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | MAN1B1 802/4885FUCA1 500/4885GBA1 175/4885 |
| US-20060134151-A1 | Novel sulfamide derivatives and cosmetic use thereof | STS, TST, TPST2 | MAN1B1 802/4885FUCA1 500/4885GBA1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.